Quebec drug maker Jamp Pharma Corp. is reminiscent of one Jamp-Pregabalin pain medication, as bottles labeled with 50 milligram capsules may instead contain 150 milligram capsules.
Health Canada announced the recall in a rare Saturday night statement.
The announcement said the company's disruption could lead to patients taking much greater painkillers than they were prescribed, posing an overdose that “could pose a serious and fatal health risk.”
Jamp-Pregabalin is an adult prescription drug. It is used to treat pain caused by diabetes, shingles, and nerve damage caused by spinal cord injury. It is also used to treat pain associated with fibromyalgia, Health Canada said.
The recall affects one of the 50 mg capsules equipped with lot number 2305012747, which holds the 2026-08 expiration date, Health Canada said.
Health Canada stressed that taking too much pregabalin or sudden increase in doses could potentially cause patients to overdose. This can be life-threatening.
Get weekly health news
Receive the latest medical news and health information provided every Sunday.
The government urged both ordinary patients, such as pharmacists, and healthcare professionals, to check the contents of the Jump Pragevalin 50 mg bottle and see if it contains 150 mg capsules.
150 mg jamp-pregabalin pain medication.
Health Canada
The agency warned that symptoms of pregabalin overdose can include sudden mood changes, drowsiness, confusion, depression, agitation, restlessness and seizures. Anyone taking medication experiencing such symptoms was urged to seek immediate medical consultation.
He also said that taking too much pregabalin while taking other drugs that act on the central nervous system, including opioids, “is linked to heart electrical issues, seizures and death.”
Trend now
Donald Trump posts his own image as Pope, causing criticism
The majority of Canadians say misinformation has affected federal elections: polls
Patients should not suddenly stop taking pregabalin as they can cause withdrawal symptoms such as insomnia, nausea, headache, anxiety, excessive sweating, diarrhea, and cramps.
“This recall was launched proactively and voluntarily on Friday following discussions with Health Canada. Please note that to our knowledge, patients have not been affected by this situation. We took immediate action in cooperation with Health Canada to ensure patient safety.”
The number of bottles of medicine and capsules contained in the recalled lot is unknown.
Health Canada said it is monitoring Jump Pharma's recall and mixing investigations.
Patients are advised to check the drug bottle or package it very carefully.
“If the prescription is for a 50 mg capsule and the bottle contains 150 mg capsules, or if you're unsure, we'll return it to the pharmacy immediately,” Health Canada said. “If you are unable to return the capsule to the pharmacy immediately, consult your pharmacist or doctor for further guidance.”
More Video Details
&Copy 2025 Global News, a division of Corus Entertainment Inc.
